Clinical Trial Search

Primary: Estimated Steady-State Maximum Plasma Concentration (Cmax,ss) of Sunitinib and Its Metabolite — 37.98; 14.55 nanograms per milliliter (ng/mL)

Primary: Maternal Cytokine IL-10 Levels of pg/ml Upon Enrollment — 12.7; 14.2 pg/ml

Primary: Number of Participants Experiencing Immune Reconstitution — 30 Participants

Primary: Objective Response Rate (ORR) — 47.5; 46.2; 43.6 Percentage of participants — p=0.5543

Primary: Percentage of Patients Free From Breast Cancer — 89.1; 93.1 percentage of participants event-free

Primary: Number of Subjects With Change From Baseline in the Mucinous Glycoprotein 1 (MUC1) Specific Systemic T-Cells Immune Response at Day 60 (Pre-Radiation) — 2; 3 Participants

Primary: Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) — -18.7; -39.8; -47.2; -54.6 Percentage Change — p=<0.001

Primary: Pain Score Assessed Immediately Following IUD Insertion — 5; 6 units on visual analog scale

Primary: % of Mean Difference in T Concentration Compared to Plain Collection Tube — 8.6; 16.6; 23.2 Difference as % of Mean of T results

Primary: Number of Days to Lesion Resolution in Combined Treatment Arms Compared to the Placebo Arm. — 10.8; 10.9; 9.35 Days — p=0.77

Primary: Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control…

Primary: Frequency of Subjects With a Deterioration of Hearing Threshold at Day 35 (Air Conduction) — 10; 2; 2 Number subject affected — p=0.128

Primary: Tacrolimus Bioavailability (F) — 0.224; 0.681 ratio of oral to IV — p=0.006

Primary: Number of Participants That Have a T790M Mutation on Their Progression Biopsy. — 4 Participants

Primary: Technician Experience With Mask — 8.46; 8.24 Units on a Scale